

Table SI. Baseline characteristics of patients with chronic hepatitis B stratified according to different grades of necroinflammation.

| Variable | All patients (n=96) | Patients without significant inflammation (n=73) |
|--------------------|------------------------|--|
| Platelet count | 0.016 | 0.114 |
| Hyaluronic acid | 0.017 | 0.002 |
| Type 4 collagen 7S | 0.004 | 0.014 |
| PIIINP | 0.029 | 0.003 |
| TIMP-1 | 0.002 | <0.001 |
| ProC3 | <0.001 | <0.001 |
| FIB4 | <0.001 | 0.015 |
| APRI | 0.093 | 0.038 |
| ELF score | 0.072 | 0.043 |

PIIINP, type 3 procollagen-N-peptide; TIMP-1, tissue inhibitor of metalloproteinase 1; M2BPGi, Mac-2-binding protein glycosylation isomer; Pro-C3, N-terminal type III collagen propeptide; FIB-4, the fibrosis index based on four factors; APRI, the aspartate aminotransferase-to-platelet ratio index; ELF score, enhanced liver fibrosis score.

Table SII. Baseline characteristics of patients with chronic hepatitis B stratified according to different grades of necroinflammation.

| Variable | A0 (n=36) | A1 (n=37) | A2 (n=20) | A3 (n=3) | P-value |
|---|-------------|---------------|---------------|---------------|---------|
| Male/female ratio | 16/20 | 18/19 | 13/7 | 1/2 | NS |
| Age, years | 53.6±2.1 | 49.8±2.3 | 48.5±2.9 | 54.2±16.4 | NS |
| Platelet ($10^4/\mu\text{l}$) (10.4-37.9) | 21.1±1.0 | 19.8±0.8 | 17.3±1.2 | 17.0±3.7 | NS |
| AST (IU/l) (10-40) | 25.3±1.8 | 33.5±3.4 | 58.1±6.8 | 102.3±32.9 | <0.001 |
| ALT (IU/l) (5-45) | 22.2±1.6 | 39.6±6.0 | 78.0±13.0 | 223.3±100.1 | <0.001 |
| Serum albumin (g/dl) (3.7-5.5) | 4.2±0.1 | 4.2±0.1 | 4.0±0.1 | 4.0±0.3 | NS |
| Total Bilirubin (mg/dl) (0.3-1.2) | 0.8±0.1 | 0.8±0.1 | 1.0±0.1 | 0.8±0.1 | NS |
| HBV DNA (Log copies/ml) | 3.6±0.4 | 5.0±0.4 | 6.4±0.6 | 7.6±0.6 | <0.001 |
| HBsAg (IU/ml) (<0.05) | 8,322±3,680 | 43,521±29,036 | 19,702±12,784 | 29,391±25,154 | NS |
| Hyaluronic acid (ng/ml) (<50.0) | 55.9±17.8 | 52.7±7.3 | 152.7±46.5 | 340.0±283.3 | 0.01 |
| Type 4 collagen 7S (ng/ml) (<6.0) | 3.5±0.2 | 4.0±0.2 | 6.0±0.9 | 5.8±0.6 | <0.001 |
| PIIINP (ng/ml) (3.62-9.52) | 7.8±0.4 | 9.4±0.7 | 16.1±2.3 | 17.6±1.5 | <0.001 |
| TIMP-1 (ng/ml) | 202.2±10.1 | 211.3±7.1 | 275.2±22.4 | 330.7±62.5 | <0.001 |
| M2BPGi (COI) (<1.00) | 0.69±0.06 | 0.74±0.07 | 1.27±0.13 | 1.84±0.42 | <0.001 |
| ProC3 (ng/ml) | 16.9±1.0 | 17.0±0.8 | 15.6±1.1 | 15.5±0.1 | NS |
| Fib4 | 1.52±0.12 | 1.57±0.17 | 2.46±0.48 | 2.47±1.06 | NS |
| APRI | 0.40±0.03 | 0.57±0.06 | 1.34±0.26 | 1.97±0.54 | <0.001 |
| ELF score | 8.90±0.14 | 9.18±0.12 | 10.19±0.30 | 10.84±0.94 | <0.001 |

Data are presented as the mean \pm standard error of mean. AST, aspartate aminotransferase; ALT, alanine aminotransferase; PIIINP, type 3 procollagen-N-peptide; TIMP-1, tissue inhibitor of metalloproteinase 1; M2BPGi, Mac-2-binding protein glycosylation isomer; Pro-C3, N-terminal type III collagen propeptide; FIB-4, fibrosis index based on four factors; APRI, aspartate aminotransferase-to-platelet ratio index; ELF score, enhanced liver fibrosis score; NS, not significant.